1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 5,150 | 7,200 | 11.08. |
► 11.08.: | | | | | | | | |
► 10.08.: | | | | | | | | | 17:30
► Aktueller 4BASEBIO Börsenkurs + Xetra-Orderbuch
► 10.08.: | | | | | | | | | 17:30
► Aktueller 4BASEBIO Börsenkurs + Xetra-Orderbuch
| Stück | Geld | Kurs | Brief | Stück |
|---|---|---|---|---|
| 35,000 | 6 | |||
| 33,000 | 33 | |||
| 22,200 | 30 | |||
| 15,000 | 15 | |||
| 11,000 | 500 | |||
| 6,350 | 500 | |||
| 6,150 | 715 | |||
| 6,000 | 7 | |||
Quelle: [URL] https://aktienkurs-orderbuch.finanznachrichten.de/88q.htm [/URL] | ||||
| 715 | 5,800 | |||
| 700 | 4,740 | |||
| 1.061 | 0,001 | |||
| Summe Aktien im Kauf | Verhältnis | Summe Aktien im Verkauf | ||
| 2.476 | 0,729 | 1.806 | ||
| Uhrzeit | Aktienkurs | Stück |
|---|---|---|
Keine Umsätze verfügbar. | ||
| Tagesumsatz Xetra | +0,300 +5,45 % | 0 |
Angaben in grüner Schrift zeigen, dass der Aktienkurs im Vergleich zum vorherigen Kurs gestiegen ist. Angaben in roter Schrift zeigen gefallene Börsenkurse.
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.07. | 4basebio Plc - Grant of Options & Director/PDMR Dealing | 366 | PR Newswire | 4basebio Plc - Grant of Options & Director/PDMR Dealing
PR Newswire
LONDON, United Kingdom, July 22
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 08.07. | 4basebio Plc - Director Appointment | 581 | PR Newswire | 4basebio Plc - Director Appointment
PR Newswire
LONDON, United Kingdom, July 08
4basebio PLC
("4basebio" or the "Company")
... ► Artikel lesen | |
| 30.06. | 4basebio Plc - Result of AGM & Issue of Options | 416 | PR Newswire | 4basebio Plc - Result of AGM & Issue of Options
PR Newswire
LONDON, United Kingdom, June 30
4basebio PLC
("4basebio"... ► Artikel lesen | |
| 4BASEBIO Aktie jetzt für 0€ handeln | |||||
| 16.06. | 4basebio Plc - Notice of Investor Presentation | 406 | PR Newswire | 4basebio Plc - Notice of Investor Presentation
PR Newswire
LONDON, United Kingdom, June 16
4basebio... ► Artikel lesen | |
| 15.06. | IN BRIEF: 4basebio appoints Jeff Coller to Strategic Advisory Board | 1 | Alliance News |
1 2 3 4 5 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Zeit | Aktuelle Nachrichten | Medien | ||
|---|---|---|---|---|
| Di | Vor Biopharma: Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | GlobeNewswire (Europe) | Enrollment on track for Phase 3 UPSTREAM MG trial of telitacicept in generalized myasthenia gravis patients with topline results anticipated in 1H27 Enrollment ongoing for Phase 3 UPSTREAM SjD of... ► Artikel lesen | |
| Di | Microbot Medical Inc.: Microbot Medical Files 10-Q, Reports Significant Revenue and Customer Growth During the 2026 Second Quarter | GlobeNewswire (Europe) | Revenue increased by more than 100% over the prior fiscal quarter, driven by repeat orders, expanded utilization among existing customers, and the acquisition of new customers since the Full Market... ► Artikel lesen | |
| Di | PDS Biotechnology Corporation: PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 | GlobeNewswire (Europe) | PRINCETON, N.J., Aug. 11, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on developing targeted... ► Artikel lesen | |
| Di | Clearmind Medicine Inc.: Clearmind Medicine Announces Positive Permeation Results for Intranasal MEAI Formulation, Supporting Enhanced Nasal Retention Without Compromising Drug Delivery | GlobeNewswire (Europe) | Vancouver, Canada, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND, FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and... ► Artikel lesen | |
| Di | Arch Biopartners to Expand Phase II Cardiac Surgery-Associated Acute Kidney Injury Trial to the United States | GlobeNewswire (Europe) | TORONTO, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (TSX Venture: ARCH and OTCQB: ACHFF) today announced that the Company will expand its ongoing Phase II trial of LSALT peptide targeting... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu 4BASEBIO PLC finden Sie auf Wallstreet Online.